Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
Blocked me too, I use twitter but don’t have many followers as I use it to just follow a couple of subjects, so I guess it’s easy to look like one of the infamous trolls, unblock me and I’ll happily vote RAH
RAH, okay, I was only playing out the serious worst case given we’ve seen a 3 week lead in to recruitment on some of the recent recruitment forms. I’m still hopeful for soon , tomorrow even. But I’m happily holding and waiting with no ‘concerns’
Sounds genuine enough to me, but it’s the kind of stock answer a tired dr who had heard fleetingly of Ava6000 would give. We can’t expect everyone to be as up to date and onboard as us ‘waiting with baited breathe’ shareholders.
Is it to obvious to suggest a lump just under the skin would be fairly straight forward to biopsy? So activation in the Tme has been confirmed in this cancer types case . It could be a contributing factor to its selection at the very least..
I’d agree with what you’ve said sorcerer, I’d just add that if each cohort goes to the maximum life time dose of doxorubicin as the dose escalates the length of time each cohort takes to reach the lifetime dose of doxorubicin also decreases. I think there can only be 3 cycles of this DE cohort before this level is met. So we’re looking at 6-9 weeks plus some data collation time until the readout. All barring any hold ups..
Has anyone else noticed in the more recent updates the mention of dose escalation has be sparse to none existent but there is still frequent mention of 3-4 cohorts? Could they be happy with the present dose and have started a third and even forth cohort at this dose and not be reaching a maximum tolerated dose. This theory at least makes sense of the timelines and communication from Avacta.